These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 26447989)

  • 21. 1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis.
    Stone GW; Gao R; Kimura T; Kereiakes DJ; Ellis SG; Onuma Y; Cheong WF; Jones-McMeans J; Su X; Zhang Z; Serruys PW
    Lancet; 2016 Mar; 387(10025):1277-89. PubMed ID: 26825231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Selection Preference on Longer-Term Outcomes between Bioresorbable Vascular Scaffold versus Everolimus-Eluting Stent for True Lumen Tracking-Recanalized Chronic Total Occlusion.
    Cheng JF; Lee CL; Chiang JY; Wu CK; Wang YC; Tsai CT; Liu SC; Tsai CT; Chang CJ; Hwang JJ
    Int Heart J; 2023; 64(2):154-163. PubMed ID: 37005311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential thrombotic prolapse burden in either bioresorbable vascular scaffolds or metallic stents implanted during acute myocardial infarction: The snowshoe effect: Insights from the maximal footprint analysis.
    Diletti R; van der Sijde J; Karanasos A; Fam JM; Felix C; van Mieghem NM; Regar E; Rapoza R; Zijlstra F; van Geuns RJ
    Int J Cardiol; 2016 Oct; 220():802-8. PubMed ID: 27394977
    [TBL] [Abstract][Full Text] [Related]  

  • 24. One-Year Clinical and Computed Tomography Angiographic Outcomes After Bioresorbable Vascular Scaffold Implantation During Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction: The PRAGUE-19 Study.
    Widimsky P; Petr R; Tousek P; Maly M; Linkova H; Vrana J; Hajsl M; Budesinsky T; Lisa L; Kocka V
    Circ Cardiovasc Interv; 2015 Dec; 8(12):e002933. PubMed ID: 26628591
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the everolimus-eluting bioresorbable vascular scaffold versus the everolimus-eluting metallic stent in real-world patients with ST-segment elevation myocardial infarction.
    Desperak P; Hawranek M; Chodór PA; Świątkowski A; Kowalczyk J; Lekston A; Gąsior M
    Postepy Kardiol Interwencyjnej; 2020 Mar; 16(1):49-57. PubMed ID: 32368236
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decision Analytic Markov Model Weighting Expected Benefits and Current Limitations of First-Generation Bioresorbable Vascular Scaffolds: Implications for Manufacturers and Next Device Iterations.
    Capodanno D; Buccheri S; Romano S; Capranzano P; Francaviglia B; Tamburino C
    Circ Cardiovasc Interv; 2018 Jan; 11(1):e005768. PubMed ID: 29326152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vascular response to everolimus- and biolimus-eluting coronary stents versus everolimus-eluting bioresorbable scaffolds--an optical coherence tomography substudy of the EVERBIO II trial.
    Kallinikou Z; Arroyo D; Togni M; Lehman S; Corpataux N; Cook M; Müller O; Baeriswyl G; Stauffer JC; Goy JJ; Puricel SG; Cook S
    Swiss Med Wkly; 2016; 146():w14274. PubMed ID: 26766027
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The EXAMINATION trial (Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-Segment Elevation Myocardial Infarction): 2-year results from a multicenter randomized controlled trial.
    Sabaté M; Brugaletta S; Cequier A; Iñiguez A; Serra A; Hernádez-Antolín R; Mainar V; Valgimigli M; Tespili M; den Heijer P; Bethencourt A; Vázquez N; Backx B; Serruys PW
    JACC Cardiovasc Interv; 2014 Jan; 7(1):64-71. PubMed ID: 24332423
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-Term Clinical Outcomes After Bioresorbable Vascular Scaffold Implantation for the Treatment of Coronary In-Stent Restenosis: A Multicenter Italian Experience.
    Moscarella E; Ielasi A; Granata F; Coscarelli S; Stabile E; Latib A; Cortese B; Tespili M; Tanaka A; Capozzolo C; Caliendo L; Colombo A; Varricchio A
    Circ Cardiovasc Interv; 2016 Apr; 9(4):e003148. PubMed ID: 27059683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Everolimus-eluting Bioresorbable Vascular Scaffold Implantation in Real World and Complex Coronary Disease: Procedural and 30-day Outcomes at Two Australian Centres.
    Robaei D; Back LM; Ooi SY; Pitney MR; Jepson N
    Heart Lung Circ; 2015 Sep; 24(9):854-9. PubMed ID: 25778622
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early and late optical coherence tomography findings following everolimus-eluting bioresorbable vascular scaffold implantation in myocardial infarction: a preliminary report.
    Karanasos A; Muramatsu T; Diletti R; Nauta S; Onuma Y; Lenzen M; Nakatani S; Van Mieghem NM; Schultz C; De Jaegere PP; Serruys PW; Zijlstra F; Regar E; van Geuns RJ
    Hellenic J Cardiol; 2015; 56(2):125-35. PubMed ID: 25854441
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry.
    Capodanno D; Gori T; Nef H; Latib A; Mehilli J; Lesiak M; Caramanno G; Naber C; Di Mario C; Colombo A; Capranzano P; Wiebe J; Araszkiewicz A; Geraci S; Pyxaras S; Mattesini A; Naganuma T; Münzel T; Tamburino C
    EuroIntervention; 2015 Feb; 10(10):1144-53. PubMed ID: 25042421
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bioresorbable vascular scaffolds for the treatment of coronary artery disease: Clinical outcomes from randomized controlled trials.
    Rizik DG; Hermiller JB; Kereiakes DJ
    Catheter Cardiovasc Interv; 2016 Nov; 88(S1):21-30. PubMed ID: 27797464
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of diabetes on the benefits from everolimus-eluting stent as compared to first-generation drug-eluting stent in patients with ST elevation myocardial infarction.
    De Luca G; Sauro R; Capasso M; Lanzillo T; Manganelli F; Carbone G; Lanni F; Pagliuca MR; Palmieri V; Serino V; Rosato G; Suryapranata H; Di Lorenzo E
    Diab Vasc Dis Res; 2015 Sep; 12(5):306-14. PubMed ID: 26150193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bioresorbable everolimus-eluting vascular scaffold in patients with ST-segment elevation myocardial infarction: Optical coherence tomography evaluation and clinical outcomes.
    Kochman J; Tomaniak M; Pietrasik A; Kołtowski Ł; Rdzanek A; Huczek Z; Mazurek T; Jąkała J; Ząbek A; Legutko J; Kochman W; Filipiak KJ
    Cardiol J; 2015; 22(3):315-22. PubMed ID: 25428734
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: insights from the ABSORB and SPIRIT trials.
    Tanimoto S; Serruys PW; Thuesen L; Dudek D; de Bruyne B; Chevalier B; Ormiston JA
    Catheter Cardiovasc Interv; 2007 Oct; 70(4):515-23. PubMed ID: 17503509
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of in vivo acute stent recoil between the bioresorbable everolimus-eluting coronary scaffolds (revision 1.0 and 1.1) and the metallic everolimus-eluting stent.
    Onuma Y; Serruys PW; Gomez J; de Bruyne B; Dudek D; Thuesen L; Smits P; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia H; Ormiston JA;
    Catheter Cardiovasc Interv; 2011 Jul; 78(1):3-12. PubMed ID: 21413120
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial.
    Sabate M; Cequier A; Iñiguez A; Serra A; Hernandez-Antolin R; Mainar V; Valgimigli M; Tespili M; den Heijer P; Bethencourt A; Vazquez N; Gómez-Hospital JA; Baz JA; Martin-Yuste V; van Geuns RJ; Alfonso F; Bordes P; Tebaldi M; Masotti M; Silvestro A; Backx B; Brugaletta S; van Es GA; Serruys PW
    Lancet; 2012 Oct; 380(9852):1482-90. PubMed ID: 22951305
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Polymeric Bioresorbable Vascular Scaffold Versus an Everolimus-Eluting Stent in ST-Segment Elevation Myocardial Infarction.
    Wernly B; Latib A; Ielasi A; Jung C
    J Invasive Cardiol; 2019 Sep; 31(9):E271-E272. PubMed ID: 31478894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ST-segment elevation myocardial infarction – ideal scenario for bioresorbable vascular scaffold implantation?
    Scalone G; Brugaletta S; Gómez-Monterrosas O; Otsuki S; Sabate M
    Circ J; 2015; 79(2):263-70. PubMed ID: 25744740
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.